Histogen, Inc., a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body, today announced it has expanded its partnership with leading global biopharmaceutical company, Allergan, Inc.. The companies originally partnered in 2017 when Allergan acquired exclusive rights to develop and commercialize Histogen’s CCM technology to health care practitioners (“HCPs”) in the aesthetic field. Over the past year, Allergan licensed additional rights to commercialize Histogen’s CCM in new distribution channels such as digital platforms, spas and salons. In this latest expansion, Allergan has gained exclusive rights to incorporate and commercialize Histogen’s CCM in microdermabrasion therapies and exclusive rights to new Histogen intellectual property in the aesthetic field.
Since the original partnership, Allergan’s focus has been incorporating CCM into new products in its SkinMedica® line including TNS® Advanced+ Serum, a next-generation version of Allergan’s best-selling TNS Essential Serum® set for launch in the first half of 2020. TNS® Advanced+ Serum, which is clinically proven to smooth the appearance of wrinkles and fine lines, target dermal sagging, and rejuvenate skin, offers significant advantages over its widely popular predecessor and will be distributed through Allergan’s network of leading HCPs. Allergan’s HCP-focused SkinMedica® business remains the foundation of Allergan’s skin care business.
Over the past year Allergan has obtained rights to commercialize CCM through new distribution channels including digital platforms (such as Amazon’s Professional Beauty storefront) as well as brick-and-mortar establishments such as spas and salons. This expansion allows Allergan to incorporate CCM into new product lines outside of its core SkinMedica® business to offer consumers a wider range of skin care solutions.
With the latest expansion, Allergan now has exclusive rights to incorporate and commercialize CCM in dermabrasion therapies such as its recently launched DiamondGlow system, secured through its 2019 acquisition of Envy Medical. In addition, Allergan has licensed exclusive rights to new Histogen intellectual property claiming novel formulations for use in the aesthetics field. Allergan believes it can leverage such novel intellectual property to develop innovative new skin care product lines in the future.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“Securing Allergan’s expanded rights to the Histogen CCM technology is a testament to our commitment to cutting edge innovation. And our excitement around Histogen continues to grow, as we first launched it in our Post Procedure 360 line this year and plan to expand it into our next generation TNS® and DiamondGlow serums in several distribution channels,” said Carrie Strom, SVP, U.S. Medical Aesthetics at Allergan.
“We are very pleased to announce our expanded partnership with Allergan. Given Allergan’s commitment to providing differentiated evidence-based skin care products, we believe that this partnership can maximize the potential for our multipotent cell conditioned media in these markets,” said Richard Pascoe, Chairman and CEO of Histogen. “Moreover, this agreement has enabled Histogen to strengthen its balance sheet with non-dilutive capital as we look to drive value with our pipeline.”
On January 28, 2020, Histogen announced that it has entered into a definitive agreement with Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) pursuant to which Histogen will merge with and into a wholly-owned subsidiary of Conatus in an all-stock transaction. The combined company is expected to operate under the name “Histogen Inc.”, and after closing, the combined company is expected to change its trading symbol to “HSTO” and trade on the Nasdaq Capital Market, and to focus on advancement of its patented technology for dermatological and orthopedic indications (including pursuing clinical trials for three key product indications in 2020), hair growth, dermal filler and joint cartilage regeneration.
Source: BioSpace